Ryan Dittamore
MBA
Chief Executive Officer
👥Biography 个人简介
Ryan Dittamore leads Epic Sciences, which developed the no-cell-left-behind platform that analyzes every nucleated cell in a blood sample to detect rare CTCs missed by enrichment-based approaches. His company commercialized the AR-V7 nuclear protein CTC test that guides treatment selection between taxanes and androgen receptor-targeted therapies in metastatic prostate cancer. He has driven regulatory approval and clinical adoption of CTC-based companion diagnostics.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ryan Dittamore 的研究动态
Follow Ryan Dittamore's research updates
留下邮箱，当我们发布与 Ryan Dittamore（Epic Sciences）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment